Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures
Status:
Completed
Trial end date:
2012-01-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an
effective adjunct therapy in the treatment of refractory partial seizures